Market revenue in 2023 | USD 115.6 million |
Market revenue in 2030 | USD 655.5 million |
Growth rate | 28.1% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.09% in 2023. Horizon Databook has segmented the Thailand cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Thailand is one of the fastest-growing economies globally and the second largest among Southeast Asian countries. The country offers low-cost manufacturing activities, witnessing a steady increase in pharmaceutical contract development & manufacturing services.
Some of the leading companies are Boehringer Ingelheim GmbH, Lonza AG, and Thermo Fisher Scientific, Inc. Thailand has been focusing on improving its healthcare infrastructure and promoting high-quality drug production, attracting international pharmaceutical companies to partner with local manufacturers for cell and gene therapy CDMOs.
Major players in the cell & gene therapy CDMO market are expanding their manufacturing capabilities and capacities to meet the increasing demand for pharmaceuticals in Thailand.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Thailand cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account